Medical Advocates

Tenofovir Disoproxil Fumarate
(Viread)
   
Journal Citations
 
General Reports           
Animal Studies             

Safety   
Pharmacokinetics
Dosing
Drug Interactions
Resistance
Viral Dynamics
Efficacy
Adverse Events
 
Diagnostics/Monitoring
Therapeutic Strategies
Discontinuation
Adherence
Prophylaxis
Drug Comparisons
Pharmacogenetics
Economics

Vaginal Products

 

Tenofovir Main Page Main New/Newsworthy  Home Page      

Last Update:  July 22, 2017
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

 
In vivo genotoxicity evaluation of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) alone and in their clinical combinations in Drosophila melanogaster.
de Moraes Filho AV, de Jesus Silva Carvalho C,  
Mutat Res. 2017 Aug;820:31-38. 5
Abstract

Nanoemulgel using a bicephalous heterolipid as a novel approach to enhance transdermal permeation of tenofovir.
Rambharose S, Kalhapure RS, Govender T. Colloids Surf B
Biointerfaces
. 2017 Mar 19;154:221-227.
Abstract

Tenofovir prodrugs: similar but not the same.
Bruggemans A, Debyser Z.
Lancet HIV
. 2017 Mar 1
Abstract

Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study.
Béguelin C, Friolet N, Moradpour D,  et al
Clin Infect Dis
. 2017 Feb 11.
Abstract

FULL-TEXT ARTICLE
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS, Chang SY, Sheng WH et al

PLoS One
. 2016 Dec 29;11(12):e0169228
Paper

Tenofovir containing thiolated chitosan core/shell nanofibers: in vitro and in vivo evaluations.
Meng J, Agrahari V, Ezoulin MJ,  et al
Mol Pharm. 2016 Oct 4.
Abstract

Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation.
Sládková V, Dammer O, Kratochvíl B.

J Pharm Sci
. 2016 Aug 10.
Abstract

Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
Giesler KE, Marengo J, Liotta DC.

J Med Chem
. 2016 Jul 13.
Abstract

Longitudinal Increase in Vitamin D Binding Protein Levels after Initiation of Tenofovir/Lamivudine/Efavirenz among Individuals with HIV
Hsieh E, Fraenkel L, Han Y, et al

AIDS
. 2016 Apr 27.
Abstract

Asymmetric Hydrogenation of α-Purine Nucleobase-Substituted Acrylates with Rhodium Diphosphine Complexes: Access to Tenofovir Analogues.
Sun HL, Chen F, Xie MS, et al
Org Lett. 2016 Apr 26.
Abstract

The influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Rungtivasuwan K, Avihingsanon A, Thammajaruk N,. et al
Antimicrob Agents Chemother. 2015 Mar 23
Abstract

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
Sirirungsi W, Urien S, Harrison L,  et al
J Acquir Immune Defic Syndr. 2014 Dec 31.
Abstract

Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
Todd CS, Deese J, Wang M,  et al

Contraception
. 2014 Oct 22. pii: S0010-7824(14)00732-X.
Abstract

FULL-TEXT ARTICLE
The role of drug transporters in the kidney: lessons from tenofovir
Moss DM, Neary M, Owen A.

Front Pharmacol
. 2014 Nov 11;5:248. eCollection 2014


FULL-TEXT ARTICLE
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS, Chang SY, Sheng WH et al

PLoS One
. 2016 Dec 29;11(12):e0169228

FULL-TEXT ARTICLE
Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study.
Richardson-Harman N, Hendrix CW, Bumpus NN, et al

PLoS One
. 2014 Oct 28;9(10):e111507||
Paper

HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial.
Garrett NJ, Werner L, Naicker N,  et al
J Acquir Immune Defic Syndr. 2014 Sep 22
Abstract

Effects of Tenofovir on Cytokines and Nucleotidases in HIV-1 Target Cells and the Mucosal Tissue Environment in the Female Reproductive Tract.
Biswas N, Rodriguez-Garcia M, Shen Z, et al

Antimicrob Agents Chemother
. 2014 Aug 18.
Abstract

FULL-TEXT ARTICLE
Vitamin D Deficiency Aggravates Nephrotoxicity, Hypertension and Dyslipidemia Caused by Tenofovir: Role of Oxidative Stress and Renin-Angiotensin System.
Canale D, de Bragança AC, Gonçalves JG, et al

PLoS One
. 2014 Jul 21;9(7):e103055
Paper

FULL-TEXT ARTICLE
Sex Hormones Regulate Tenofovir-Diphosphate in Female Reproductive Tract Cells in Culture.
Shen Z, Fahey JV, Bodwell JE,  et al

PLoS One
. 2014 Jun 30;9(6):e100863.
Paper

FULL-TEXT ARTICLE
Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients:
A Feasibility Study and Call for a Trial.
Achhra AC, Boyd MA, Law MG, et al

PLoS One
. 2014 Jun 26;9(6):e99530.
Paper

Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Dang NT, Sivakumaran H, Harrich D, et al

Eur J Pharm Biopharm
. 2014 May 30.
Abstract

Evaluation of degradation kinetics and physicochemical stability of tenofovir.
Agrahari V, Putty S, Mathes C, et al 

Drug Test Anal
. 2014 May 12.
Abstract

Effects of a Protein-Rich Drink or a Standard Meal on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir in
 Healthy Japanese Male Subjects: A Randomized, Three-Way Crossover Study.

Shiomi M, Matsuki S, Ikeda A,  et al
J Clin Pharmacol. 2014 Mar 11.
Abstract

Incomplete reversibility of eGFR following tenofovir exposure.
Jose S, Hamzah L, Campbell L, Hill T,  et al

J Infect Dis
. 2014 Feb 28
Abstract

FULL-TEXT ARTICLE
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
Gervasoni C, Meraviglia P, Landonio S,
et al
PLoS One. 2013 Dec 2;8(12):e80242
Paper

Urine L-FABP and KIM-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
Jabłonowska E, Wójcik K, Piekarska A.
AIDS Res Hum Retroviruses
. 2013 Oct 28.
Abstract

Formulation and Evaluation of Mucoadhesive Microspheres of Tenofovir Disoproxil Fumarate for Intravaginal Use.
Khan AB, Thakur RS.
Curr Drug Deliv
. 2013 Oct 28.
Abstract

A clinical prediction score for targeted creatinine testing prior to initiating tenofovir-based antiretroviral treatment in Cambodia.
van Griensven J, Phirum L, Thai S, et al
J Acquir Immune Defi
c Syndr
. 2013 Oct 10
Abstract

Impact on L-carnitine Homeostasis of Short-term Treatment with the Pivalate Prodrug Tenofovir Dipivoxil.
Jia YY, Lu CT, Feng J,  et al
Basic Clin Pharmacol Toxicol. 2013 Jul 15
Abstract

FULL-TEXT ARTICLE
The Effect of Tenofovir on Vitamin D Metabolism in HIV-Infected Adults Is Dependent on Sex and Ethnicity.
Klassen K, Martineau AR, Wilkinson RJ, Cooke G, et al
PLoS One
. 2012;7(9):e44845.
Paper

Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
[
No authors listed]
Antivir Ther
. 2012 Aug 15.
Abstract

Chemico-physical investigation of tenofovir loaded polymeric nanoparticles.
Belletti D, Tosi G, Forni F, et al
Int J Pharm. 2012 Aug 4."
Abstract

Understanding the molecular mechanism of sequence dependent Tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.
I
yidogan P, Anderson KS.
Antiviral Res
. 2012 Jun 1
Abstract

Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS, Rohan LC, Wang L, et al
J Antimicrob Chemothe
r
. 2012 May 11.
Abstract

Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?
De Clercq E.
Med Res Rev
. 2012 May 11.
Abstract

Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir.
Bech A, Van Bentum P, Nabbe K, et al
HIV Med
. 2012 Mar 30.
Abstract

Low concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir
Best BM, Letendre SL, Koopmans P, et al
J Acquir Immune Defic Syndr
. 2012 Jan 3
Abstract

Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Kim C, Gupta SK, Green L, et al
Antivir Ther
. 2011;16(8):1335-9.
Abstract

Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring.
Moss JA, Malone AM, Smith TJ,  et al
Antimicrob Agents Chemother
. 2011 Nov 28.
Abstract

FULL-TEXT ARTICLE
Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand.
Martin M, Vanichseni S, Suntharasamai P. et al
PLoS One
. 2011;6(9):e25127
Paper

The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells.
Brüning A, Burger P, Gingelmaier A, Mylonas I.
Invest New Drugs. 2011 Jun 29.
Abstract

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients
switching to abacavir or tenofovir.
Saumoy M, Ordońez-Llanos J, Martínez E, et al
Antivir Ther
. 2011;16(4):459-468.

Abstract

Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12 / IL-10 balance in human primary cells
Melchjorsen J, Risřr MW, Sřgaard OS, et al
J Acquir Immune Defic Syndr
. 2011 Apr 5

Abstract

Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
Alukda D, Sturgis T, Youan BB.
J Pharm Sci. 2011 Mar 15.
Abstract

Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil
fumarate in healthy volunteers.
Yerino GA, Halabe EK, Zini E, Feleder EC.
Arzneimittelforschung
. 2011;61(1):55-60.

Abstract

The Exploitation of "Exploitation" in the Tenofovir Prep Trial in Cameroon: Lessons Learned from Media Coverage of an HIV Prevention Trial.
Mack N, Robinson ET, Macqueen KM,  et al
J Empir Res Hum Res Ethics
. 2010 Jun;5(2):3-19
Abstract


Animal Studies
 

 
Tenofovir during pregnancy in rats: a novel pathway for programmed hypertension in the offspring.
Gois PH, Canale D, Luchi WM,  et al

J Antimicrob Chemother
. 2014 Dec 9
Abstract

HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M, Yang KH, LeCureux J,  et al
 
Virology
. 2014 Aug 5;464-465C:253-263
Abstract

Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Anderson PL, Glidden DV, Bushman LR, et al
J Antimicrob Chemother. 2014 May 26
Abstract

Mitochondrial Dysfunction and Electron Transport Chain Complex Defect in a Rat Model of Tenofovir Disoproxil Fumarate Nephrotoxicity.
Ramamoorthy H, Abraham P, Isaac B.

J Biochem Mol Toxicol
. 2014 Mar 10.
Abstract

FULL-TEXT ARTICLE
Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice.
Chateau ML, Denton PW, Swanson MD, et al
PLoS One. 2013;8(3):e60024.
Pape
r

Anti-viral and immunological effects of tenofovir microbicide in vaginal HSV-2 infection.
Vibholm L, Reinert LS, Sřgaard OS,  et al
AIDS Res Hum Retroviruses. 2012 Aug 6.
Abstract

Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Van Rompay KK, Trott KA, Jayashankar K, et al
Retrovirology. 2012 Jul 17;9(1):57.
Abstract

Pharmacokinetics and Topical Vaginal Effects of Two Tenofovir Gels in Rabbits.
Clark MR, Friend DR.
AIDS Res Hum Retroviruses
. 2012 Mar 6
Abstract


Safety
 

 
Comparative renal safety assessment of the hepatitis B drugs, adefovir, tenofovir, telbivudine and entecavir in rats.
Uteng M, Mahl A, Beckmann N, al

 Toxicol Sci
. 2016 Oct 13.
Abstract

A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.
Scherzer R, Gandhi M, Estrella MM,  et al

AIDS
. 2014 Jun 1;28(9):1289-1295.
Abstract

Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate (TDF) Among HIV-uninfected Men Who Have Sex With Men (MSM) in the United States.
Grohskopf LA, Chillag KL, Gvetadze R,  et al
J Acquir Immune Defic Syndr. 2013 Mar 5.
Abstract

FULL-TEXT ARTICLE
Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho.
Bygrave H, Kranzer K, Hilderbrand K,   et al
PLoS One
. 2011 Mar 2;6(3):e17609.
Paper

Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients.
Cooper RD, Wiebe N, Smith N, et al
Clin Infect Dis
. 2010 Jul 13
Abstract


The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Gallant JE, Winston JA, Dejesus E, et al
 
AIDS
. 2008 Oct 18;22(16):2155-2163
Abstract
 

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults:
the first 4 years.

Nelson MR, Katlama C, Montaner JS, et al

AIDS.
2007 Jun;21(10):1273-1281
Abstract

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled
multicentre study.
Izzedine H, Hulot JS, Vittecoq D, et al 

Nephrol Dial Transplant. 2005 Mar
Abstract


Dosing
 

  Once-daily raltegravir moving ahead.
Fernández-Montero JV.

AIDS Rev
. 2013 Oct-Dec;15(4):238-9.
Abstract

Pharmacokinetics
 

 

Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.
Du X, Kou H, Fu Q, et al
Expert Rev Clin Pharmacol. 2017 May 8.
Abstract

The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir.
Gervasoni C, Cattaneo D, Resnati C, et al 
Eur J Clin Pharmacol. 2017 Mar 6.a
Abstract

FULL-TEXT ARTICLE
Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.
Gao Y, Katz DF
PLoS One. 2017 Jan 23;12(1):e0167696. 
Paper

Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Herold BC, Chen BA, Salata RA, et al

Clin Infect Dis
. 2015 Oct 27
Abstract

Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.
Calcagno A, Cusato J, Marinaro L, et al

Pharmacogenomics J
. 2015 Oct 6.
Abstract

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate (TDF) 300 mg every 48 hours versus 150 mg once daily in HIV-infected adults with moderate renal function impairment.
Cressey TR, Avihingsanon A, Halue G,  et al
Clin Infect Dis. 2015 Apr 28.
Abstract

Population Pharmacokinetics of Tenofovir and Tenofovir-diphosphate in healthy women.
Burns RN, Hendrix CW, Chaturvedula A.

J Clin Pharmacol
. 2015 Jan 8
Abstract

FULL-TEXT ARTICLE
A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
Yang KH, Hendrix C, Bumpus N, et al

PLoS One
. 2014 Oct 28;9(10):e106196
Paper

Pharmacokinetics and Tolerability of Tenofovir Disoproxil Fumarate 300 mg Once Daily: An Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Subjects.
Hu CY, Liu YM, Liu Y, et al
Clin Ther. 2013 Oct 19.
Abstract

Association of higher plasma vitamin D binding protein and lower free calcitriol with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: Cause of a functional vitamin D deficiency?
Havens PL, Kiser JJ, Stephensen CB,   et al
Antimicrob Agents Chemother
. 2013 Sep 3

Abstract

Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women.
Dumond JB, Nicol MR, Kendrick RN, et al
Clin Pharmacokinet. 2012 Oct 9
Abstract

FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection.
Duwal S, Schütte C, von Kleist M.
PLoS One
. 2012;7(7):e40382.
Paper

A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study.
Matta MK, Burugula L, Pilli NR, et al
Biomed Chromatogr
. 2012 Jan 4. 
Abstract

Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.
Moss JA, Baum MM, Malone AM,  et al
AIDS
. 2011 Dec 29.
Abstract

Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1 Infected Patients
Baheti G, Kiser JJ, Havens PL, Fletcher CV.
Antimicrob Agents Chemother. 2011 Sep 6.
Abstract

Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 - Step 2).
Hirt D, Ekouévi DK, Pruvost A,  et al
Antimicrob Agents Chemother
. 2011 Apr 4.
Abstract

Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber A, Condoluci D, Slowinski P, et al  
HIV Med
. 2009 Oct 23.
Abstract

Population Pharmacokinetics of Tenofovir in AIDS Patients.
Gagnieu MC, El Barkil M, Livrozet JM 
 
J Clin Pharmacol.
2008 Sep 8.
Abstract
 

The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract.
Vourvahis M, Tappouni HL, Patterson KB, et al 
J Acquir Immune Defic Syndr. 2008 Jan 11
Abstract
 
Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection - Study ATN056.
Kiser JJ, Fletcher CV, Flynn PM, et al 
Antimicrob Agents Chemothe
r. 2007 Nov 19;
Abstract
 
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Parks DA, Jennings HC, Taylor CW, Acosta EP.

AIDS
. 2007 Jun;21(10):1373-5.
Abstract
 
FULL-TEXT ARTICLE
The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.
Anthonypillai C, Gibbs JE, Thomas SA.
Cerebrospinal Fluid Res. 2006 Jan 3;3(1):1
Paper
 
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Jullien V, Treluyer JM, Rey E, et al
Antimicrob Agents Chemother.
2005 Aug;49(8):3361-6.
Abstract
 
Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens.
Hawkins T, Veikley W, St Claire RL 3rd , et al
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-
Abstract
 
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Smith PF, Kearney BP, Liaw S, et al 

Pharmacotherapy. 2004 Aug;24(8):970-7.
Abstract

Drug/Drug Interactions
 

 
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Khatri A, Dutta S, Dunbar M, et al
Antimicrob Agents Chemother
. 2016 Apr 22;60(5):2965-71.
Abstract

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.
Lahiri CD, Tao S, Jiang Y,  et al

AIDS
. 2015 Apr 13.
Abstract

FULL-TEXT ARTICLE
Ganciclovir-tenofovir interaction leading to tenofovir-induced nephrotoxicity
Soanker R, Udutha SJ, Subbalaxmi MV, Raju Y.

J Pharmacol Pharmacother
. 2014 Oct;5(4):265-267.
Paper

Evaluation of the Effect of Cobicistat on the In Vitro Renal Transport and Cytotoxicity Potential of Tenofovir.
Stray KM, Bam RA, Birkus G, et al
Antimicrob Agents Chemother. 2013 Jul 29
Abstract

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.
Liptrott NJ, Curley P, Moss D,  et al
J Antimicrob Chemother
. 2013 Jun 21.
Abstract

Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
Kunimoto Y, Yasui H, Touda N,  et al
J Infect Chemoth
er
. 2012 Oct 5
Abstract

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Férir G, Palmer KE, Schols D.
Virology. 2011 Jul 27
Abstract

Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir.
Moss DM, Kwan WS, Liptrott NJ, et al
Antimicrob Agents Chemother
. 2010 Nov
Abstract

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects.
Song I, Min SS, Borland J, et al
J Acquir Immune Defic Syndr
. 2010 Jun 25
Abstract

Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
Goicoechea M, Jain S, Bi L, et al 
AIDS
. 2010 Mar 13;24(5):707-716.
Abstract

Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir.
Baker J, Rainey PM, Moody DE,  et al 
Am J Addict
. 2010 Jan 1;19(1):17-29
Abstract


Viral Dynamics
 

 
Persistent viremia in HIV-hepatitis B co-infected patients undergoing long-term tenofovir: virological and clinical implications.
Boyd A, Gozlan J, Maylin S, et al

Hepatology
. 2014 Apr 19.
Abstract

A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study.
Matta MK, Burugula L, Pilli NR, et al
Biomed Chromatogr
. 2012 Jan 4. 
Abstract

Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate.
Trehanpati N, Kotillil S, Hissar SS, et al J
 lin Immunol
. 2011 Feb 9
Abstract

Antiviral Activity of Zidovudine and Tenofovir in the Presence of the K65R Mutation
in Reverse Transcriptase: An International Cohort Analysis.
Grant PM, Taylor J, Nevins AB, et al  
Antimicrob Agents Chemother
. 2010 Feb 1.
Abstract

Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir.
Bansi L, Sabin C, Gilson R,  et al
J Infect Dis. 2009 Jul 27.
Abstract

Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Balestre E, Dupon M, Capdepont S, et al  
 
J Clin Virol.
2006 Mar 21;
Abstract


Resistance
 

 

FULL-TEXT ARTICLE
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Zhang X, Li M, Xi H, et al

Oncotarget
. 2016 Sep 2
Paper

Genotypic HIV-1 drug resistance among patients failing Tenofovir based first-line HAART in South India.
Dinesha TR, Gomathi S, Boobalan J,  et al

AIDS Res Hum Retroviruses
. 2016 Jun 22.
Abstract

FULL-TEXT ARTICLE
High Prevalence of the K65R Mutation in HIV-1 Subtype C Infected Patients Failing Tenofovir-Based First-Line Regimens in South Africa.
Skhosana L, Steegen K, Bronze M,  et al

PLoS One
. 2015 Feb 6;10(2):e0118145.
Paper

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
Pingen M, Nijhuis M, Mudrikova T, et al

J Antimicrob Chemother
. 2014 Sep 26.
Abstract

Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital and Blood Compartments of Women with Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial.
Wei X, Hunt G, Karim SS,  et al

J Infect Dis
. 2014 Jan 16
Abstract

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C, and D.
Liu Y, Miller MD, Kitrinos KM.
Liver Int
. 2013 Oct 1.

Abstract

Roles of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and other Non-Nucleoside Reverse Transcriptase Inhibitors.
Xu HT, Colby-Germinario SP, Huang W,  et al
Antimicrob Agents Chemother
. 2013 Sep
3.
Abstract

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
Michailidis E, Ryan EM, Hachiya A,  et al
Retrovirology. 2013 Jun 24;10(1):65
Abstract

Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Hoffmann CJ, Ledwaba J, Li JF,  et al
Antivir Ther
. 2013 Jun 10.
Abstract

Recent findings on the mechanisms involved in tenofovir resistance.
I
yidogan P, Anderson KS.
Antivir Chem Chemother
. 2013 Jun 6.
Abstract

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A,  et al
J Antimicr
ob Chemother. 2013 Jan 29.
Abstract

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
Chan PA, Huang A, Kantor R.
J Int AIDS Soc. 2012 Oct 15;15(2):17701
Abstract

Tenofovir based regimens associated with less drug resistance in HIV-1 infected nigerians failing first-line
antiretroviral therapy.

Etiebet MA, Shepherd J, Nowak RG,  
AIDS
. 2012 Oct 17
Abstract

Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
van Bömmel F, Trojan J, Deterding K,  et al
Antivir Ther
. 2012 Aug 14.

Abstract

Clonal analysis of the quasispecies of antiviral resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Karatayli E, Idilman R, Karatayli SC, , et al
Antivir Ther
. 2012 Aug 8
Abstract

FULL-TEXT ARTICLE
K70Q Adds High-Level Tenofovir Resistance to "Q151M Complex" HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism.
Hachiya A, Kodama EN, Schuckmann MM, et al
PLoS One
. 2011 Jan 13;6(1):e16242.
Paper

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens.
Svicher V, Alteri C, Artese A, et al
J Acquir Immune Defic Syndr
. 2010 Aug 24
Abstract

Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring.
Lyagoba F, Dunn DT, Pillay D,
 et al
J Acquir Immune Defic Syndr
. 2010 Aug 3.
Abstract

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Maserati R, De Silvestri A, Uglietti A,  et al
AIDS
. 2010 Jan 30.
Abstract


Diagnostic/Monitoring
       

 
Real-Time Analysis of Tenofovir Release Kinetics Using Quantitative Phosphorus (31P) Nuclear Magnetic Resonance Spectroscopy.
Agrahari V, Meng J, Purohit SS,
J Pharm Sci. 2017 Apr 13.
Abstract

Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids.
Barreiros L, Cunha-Reis C, Silva EM,  et al
J Pharm Biomed Anal. 2016 Dec 27;136
Abstract

An Investigation of Liquid Chromatography-Mass Spectral Attributes and Analytical Performance Characteristics of Tenofovir, Emtricitabine and Efavirenz in Human Plasma.
Ndolo SM, Sichilongo K, Massele A,  et al

J Anal Toxicol
. 2015 Oct 20.
Abstract

More long-term assessment of transient elastography is needed for HIV-HBV co-infected patients undergoing treatment with tenofovir.
Boyd A, Lacombe K.  
Clin Infect Dis
. 2015 Sep 3. pii: civ767.'
Abstract

Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir and tenofovir in human plasma: Application to human pharmacokinetics.
Reddy AV, Jaafar J, Aris AB, et al
J Sep Sci
. 2015 May 18.
Abstract

Use of Micellar Liquid Chromatography to Analyze Darunavir, Ritonavir, Emtricitabine, and Tenofovir in Plasma
Peris-Vicente J, Villarreal-Traver M, Casas-Breva I,  et al

Sep Sci
. 2014 Aug 7.
Abstract

Urine processing impacts uric acid level in hiv-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy.
Hotta MT, Broderick E, Wyatt CM.
AIDS
. 2013 Mar 21
Abstract

Simultaneous analysis of antiretroviral drugs abacavir and tenofovir in human hair by liquid chromatography-tandem mass spectrometry.
Shah SA, Mullin R, Jones G,  et al
J Pharm Biomed Anal
. 2013 Feb 23;74:308-13
Abstract

Development and validation of a LC-MS/MS assay to quantify intracellular tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP).
Watson V, Else L, Tjia J, Khoo S, Back D.
J Int AIDS Soc
. 2012 Nov 11;15(6):18336
Abstract

Tenofovir, emtricitabine, and tenofovir-diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla J, Zheng JH, Rower JE,  et al
AIDS Res Hum Retroviruses. 2012 Aug 31.
Abstract

Sensitive and Rapid HPLC Quantification of Tenofovir from Hyaluronic Acid-Based Nanomedicine.
Agrahari V, Youan BB.
AAPS PharmSciTech
. 2012 Jan 4

Abstract

Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry.
Meesters RJ, van Kampen JJ, Scheuer RD, et al
J Mass Spectrom
. 2011 Mar;46(3):282-9.
Abstract

Selective Determination of Antiretroviral Agents Tenofovir, Emtricitabine, and Lamivudine in Human Plasma by a LC-MS-MS Method for a Bioequivalence Study in Healthy Indian Subjects.
Yadav M, Singhal P, Goswami S, et al

J Chromatogr Sci
. 2010;48(9):704-13.
Abstract

Development of a validated liquid chromatographic method for the determination of related
substances and assay of tenofovir disoproxil fumarate.
Ashenafi D, Chintam V, van Veghel D, et al
J Sep Sci
. 2010 May 5.
Abstract

Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem
mass spectrometry.
Jansen RS, Rosing H, Kromdijk W, et al 
J Chromatogr B Analyt Technol Biomed Life Sci
. 2010 Jan 14
Abstract

A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
D'Avolio A, Sciandra M, Siccardi M, et al
  
J Chromatogr Sci.
2008 Jul;46(6):524-8.
Abstract
 

FULL TEXT PDF ARTICLE
Determination of plasma tenofovir concentrations using a conventional LC-MS method.
Takahashi M, Kudaka Y, Okumura N,  et al
 
Biol Pharm Bull.
2007 Sep;30(9):1784-6.

Paper
 
Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring.
Barkil ME, Gagnieu MC, Guitton J.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 19;
Abstract
 
Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels.
Kinai E, Hanabusa H.

AIDS.
2005 Nov 18;19(17):2031-2033.
Abstract
 

Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction.
Rezk NL, Crutchley RD, Kashuba AD.  
J Chromatogr B Analyt Technol Biomed Life Sc
i. 2005 Jul 5;

Abstract


Therapeutic Strategies
       

 

Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B co-infected Patient.
Karris M.
AIDS Res Hum Retroviruses
. 2017 Apr 13.
Abstract

FULL-TEXT ARTICLE
Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.
Gao Y, Katz DF
PLoS One. 2017 Jan 23;12(1):e0167696. 
Paper

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
Boyd A, Piroth L, Maylin S,  et al

J Viral Hepat
. 2016 Aug 3
Abstract

Reversibility of renal dysfunction after discontinuation of tenofovir.
Cha A, Besignano-Long AR, Rothberger N, Shah B.

J Am Pharm Assoc (2003)
. 2016 Apr 7.
Abstract

Increased bone turnover after switch to tenofovir + lopinavir/ritonavir in Chinese HIV + patients.
Hsieh E, Fraenkel L, Xia W, et al
 
Ann Rheum Dis
. 2014 Mar 1;73 Suppl 1:A62.
Abstract

Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate.
Havens PL, Hazra R, Stephensen CB,  et al

Antivir Ther
. 2014 Feb 17

Abstract

Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients;
 A Substudy of the PREPARE Study.

Cotter AG, Vrouenraets SM, Brady JJ,  et al
J Clin Endocrinol Metab. 2013 Feb 22
Abstract

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Tungsiripat M, Kitch D, Glesby MJ, et al
AIDS
. 2010 May 21
Abstract


Adherence
       

 
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.
Koss CA, Bacchetti P, Hillier SL,  et al  
AIDS Res Hum Retroviruses
. 2017 Mar 2.
Abstract

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Nelson M, Girard PM, Demasi R, et al  
J Antimicrob Chemother
. 2010 May 24

Abstract


Discontinuation
       

 
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Mills A, Arribas JR, Andrade-Villanueva J,  et al 
Lancet Infect Dis. 2015 Oct 30.
Abstract

Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Hsu R, Lanier ER, Rouse EG, et al

Antivir Ther
. 2008;13(5):735-7.
Abstract

FULL-TEXT PDF DOCUMENT
Analysis of the causes and predictive factors for discontinuing treatment with tenofovir in
pretreated HIV patients.

Morillo Verdugo R, Gil Navarro MV, Abdel-Kader Martín L, et al

Farm Hosp.
2007 Aug;31(4):200-205.
Paper


Prophylaxis
       

 

FULL-TEXT ARTICLE
A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR, Siriprakaisil O, Klinbuayaem V, et al 
BMC Infect Dis
.
2017 Jul 14;17(1):496
Paper

Design and In vitro Evaluation of Tenofovir - Loaded Vaginal Gels for the Prevention of HIV Infections.
Timur SS, Şahin A, Aytekin E, Öztürk N, et al
 Pharm Dev Technol
. 2017 May 15:
Abstract

Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
Musinguzi N, Muwonge T, Thomas K,
AIDS Behav. 2016 Nov;20(11):2639-2643.
Abstract

FULL-TEXT ARTICLE
Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.
MacQueen KM, Dlamini S, Perry B, et al
AIDS Behav. 2016 Nov;20(11):2682-2691.
Paper

Rectal 1% tenofovir gel use associates with altered epidermal protein expression.
Romas L, Birse K, Mayer KH,
 et al
AIDS Res Hum Retroviruses
. 2016 June 21
Abstract

Renal Function and Tenofovir Disoproxil Fumarate for PrEP: How safe is safe enough?
Krakower DS, Mayer KH.
 
J Infect Dis
. 2016 Apr 27.
Abstract

Elevations in Serum Creatinine with Tenofovir-Based HIV Pre-exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Yacoub R, Nadkarni GN, Weikum D, et al

J Acquir Immune Defic Syndr
. 2015 Nov 30.
Abstract

Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Thomson KA, Baeten JM, Mugo NR

Curr Opin HIV AIDS
. 2015 Sep 28.
Abstract

A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
Hiruy H, Fuchs EJ, Marzinke MA,  et al
AIDS Res Hum Retroviruses. 2015 Jul 31
Abstract

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM, Donnell D, Mugo NR, et al

Lancet Infect Dis. 2014 Oct 8
Abstract

Release of Tenofovir from Carrageenan-Based Vaginal Suppositories.
Zaveri T, Hayes JE, Ziegler GR.

Pharmaceutics
. 2014 Jul 4;6(3):366-377.
Abstract

Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention.
Meng J, Zhang T, Agrahari V, Ezoulin MJ, Youan BB.

Nanomedicine
(Lond)
. 2014 Jan 10.
Abstract

FULL-TEXT ARTICLE
No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial
Chopera DR, Mann JK, Mwimanzi P, et al
PLoS One
. 2013 Aug 28;8(8):e71758.
Paper

An Evaluation of Polycaprolactone Matrices for Vaginal Delivery of the Antiviral, Tenofovir, in Preventing Heterosexual Transmission of HIV.
Dang NT, Sivakumaran H, Harrich D, Coombes AG.
J Pharm Sci
.
2013 Jul 31
Abstract

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, Martin M, Suntharasamai P,  et al
Lancet. 2013 Jun 15;381(9883):2083-90
Abstract

FULL-TEXT ARTICLE
Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis.
Chaowanachan T, Krogstad E, Ball C, Woodrow KA.
PLoS One
. 2013 Apr 22;8(4):e61416
Paper

Sexual risk behavior among HIV-uninfected men who have sex with men (MSM) participating in a tenofovir pre-exposure prophylaxis (PrEP) randomized trial in the United States.
Liu AY, Vittinghoff E, Chillag K, Mayer K,  et al
J Acquir Immune Defic Syndr
.
2013 Mar 11
Abstract

Spray Drying Tenofovir Loaded Mucoadhesive and pH-Sensitive Microspheres Intended for HIV Prevention.
Zhang T, Zhang C, Agrahari V,  et al
Antiviral Res. 2012 Dec 26.
Abstract

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
Gengiah TN, Baxter C, Mansoor LE,  et al
Expert Opin Investig Drugs
. 2012 Mar 7
Abstract

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Celum C, Baeten JM.
Curr Opin Infect Dis
. 2012 Feb;25(1):51-7.
Abstract

FULL-TEXT ARTICLE
Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.
Liu AY, Vittinghoff E, Sellmeyer DE, et al
PLoS One
. 2011;6(8):e23688.
Paper

Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
Alukda D, Sturgis T, Youan BB.
J Pharm Sci. 2011 Mar 15
Abstract

Co-enrollment in multiple HIV prevention trials - Experiences from the CAPRISA 004 Tenofovir gel trial.
Karim QA, Kharsany AB, Naidoo K,  et al
Contemp Clin Trials
. 2011 Jan 25.
Abstract

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Anderson PL, Kiser JJ, Gardner EM, et al
J Antimicrob Chemother
. 2010 Nov 30.
Abstract

 

Drug Comparison Studies
       

 
FULL-TEXT ARTICLE
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
Wang H, Lu X, Yang X,et al.
Medicine (Baltimore). 2016 Oct;95(41):e5146.
Paper

FULL-TEXT ARTICLE
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Funderburg NT, McComsey GA, Kulkarni M,  et al"

EBioMedicine
. 2016 Oct 11.
Paper

FULL-TEXT ARTICLE
Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.
Pereira CV, Tovo CV, Grossmann TK, et al
Mem Inst Oswaldo Cruz. 2016 Apr;111(4):252-7.
Paper

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Hou JL, Gao ZL, Xie Q, et al
J Viral Hepat. 2014 Sep 22.

Abstract

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Arathoon E, Schneider S, Baraldi E, Lim PL,  et al
Int J STD AIDS. 2013 Feb 25
Abstract

The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
Menezes C, Duarte R, Dickens C,  et al
HIV Med. 2012 Oct 4.
Abstract

Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Avihingsanon A, Lewin SR, Kerr S,  et al
Antivir Ther. 2010;15(6):917-22.
Abstract


Pharmacogenetics
       

 
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.
Calcagno A, Cusato J, Marinaro L, et al

Pharmacogenomics J
. 2015 Oct 6.
Abstract

Pharmacogenetics of tenofovir treatment.
Rodriguez-Novoa S, Labarga P, Soriano V.
Pharmacogenomics. 2009 Oct;10(10):1675-85.

Abstract


Economics
       

 
Making Tenofovir Accessible In The Brazilian Public Health System: Patent Conflicts And Generic Production.
Veras J.

Dev World Bioeth
. 2014 May 29
Abstract

FULL-TEXT ARTICLE
Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy
in Settings without Virological Monitoring.

von Wyl V, Cambiano V, Jordan MR,  et al
PLoS One. 2012;7(8):e42834.

Paper

Cost-Effectiveness of Tenofovir as First-Line Antiretroviral Therapy in India.
Bender MA, Kumarasamy N, Mayer KH,  et al
Clin Infect Dis. 2009 Dec 31.

Abstract


Vaginal Products
       

 

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
Klatt NR, Cheu R, Birse K,  et al 
Science
. 2017 Jun 2;356(6341):938-945.
Abstract

Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
Mugwanya KK, John-Stewart G, Baeten J.
Expert Opin Drug Saf. 2017 Jun 2.

Abstract

FULL-TEXT ARTICLE
Influence of Chitosan Swelling Behaviour on Controlled Release of Tenofovir from Mucoadhesive Vaginal Systems for Prevention of Sexual Transmission of HIV.
Notario-Pérez F, Martín-Illana A, Cazorla-Luna R, et al
Mar Drugs
. 2017 Feb 21;15(2). pii: E50
Paper

A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ, Mesquita PM, Marzinke MA, et al  

AIDS
. 2015 Nov 24.
Abstract

An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM, Butkyavichene I, Churchman SA,  et al
Int J Pharm. 2015 Sep 16.
Abstract

Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y, Yuan A, Chuchuen O,  et al

Drug Deliv Transl Res
. 2015 Apr 15.

Abstract

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention.
Clark MR, Peet MM, Davis S, et al
Pharmaceutics
. 2014 Dec 8;6(4):616-631.
Abstract

Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?
Snead MC, Kourtis AP, Melendez JH, et al
Contraception. 2014 Mar 25
Abstract

Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection.
McConville C, Boyd P, Major I.
Clin Med Insights Womens Health. 2014 Feb 13;7:1-8.
Abstract

FULL-TEXT ARTICLE
Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao Y, Katz DF.
PLoS One
. 2013 Sep 11;8(9):e74404
Paper

Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial.
Baxter C, Yende-Zuma N, Tshabalala P, Karim QA, Abdool Karim SS.
Antiviral Res. 2013 Jul 4
Abstract

A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Cohen JA, Brache V, Foster J,  et al
Sex Transm Dis. 2013 Jun;40(6):476-81.
Abstract

Adherence and Acceptability in MTN 001: A Randomized Cross-Over Trial of Daily Oral and Topical Tenofovir for HIV Prevention in Women.
Minnis AM, Gandham S, Richardson BA,  et al
AIDS Behav
. 2012 Oct 14.
Abstract

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC, Karim QA, Sibeko S,  et al
Antivir Ther
. 2012 Aug 23.
Abstract

RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir Disoproxil Fumerate.
Anton PA, Cranston RD, Kashuba A,  et al
AIDS Res Hum Retroviruses
. 2012 Sep 3.
Abstract

CAPRISA 004 Tenofovir Microbicide Trial: No impact of Tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z, Sibeko S, Anderson J,  
J Infect Dis
. 2012 May 2.

Abstract

Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Mesquita PM, Rastogi R, Segarra TJ,  et al 
J Antimicrob Chemother
. 2012 Mar 30.
Abstract

Development of a combination microbicide gel formulation containing IQP-0528 and tenofovirfor the prevention of HIV infection.
Ham AS, Ugaonkar SR, Shi L, et al
Pharm Sci
. 2012 Jan 6.
Abstract

Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication.
Andrei G, Lisco A, Vanpouille C, et al
Cell Host Microbe
. 2011 Oct 4;10(4):379-89.
Abstract

Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Williams BG, Abdool Karim SS,  et al
J Acquir Immune Defic Syndr
. 2011 Jun 7
Abstract

FULL-TEXT ARTICLE
A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel
M Keller MJ,  Madan RP Torres NM, et al
PLoS ONE 6(1): e16475
Paper


Tenofovir Main Page Main New/Newsworthy  Home Page      

Tenofovir Disoproxil Fumarate
Journal Citations